RemeGen Co. Ltd. Class A
688331
Rank in Stocks
#2414
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Share Price
$14.49
Market Cap
$8.11B
Change (1 day)
2.99%
Change (1 year)
9.18%
Country
CN
Trade RemeGen Co. Ltd. Class A (688331)
Category
Healthcare
Revenue for RemeGen Co. Ltd. Class A (688331)
Revenue in Jun 2026 TTM: $1.16B
According to RemeGen Co. Ltd. Class A latest financial reports the company's current revenue (TTM) is $1.16B. In 2023 the company made a revenue of $152.99M an increase over the revenue in the year 2022 that was $111.93M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for RemeGen Co. Ltd. Class A from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.16B | 393.27% |
| 2024 | $235.22M | 53.75% |
| 2023 | $152.99M | 36.68% |
| 2022 | $111.93M | -50.04% |
| 2021 | $224.03M | -301,419.47% |
| 2020 | $-74.35K | -119.31% |
| 2019 | $385.06K | -76.60% |
| 2018 | $1.65M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 988.08% |
US
|
|
| $2.23B | 92.03% |
US
|
|
| $15.74B | 1,256.99% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 418.97% |
NL
|
